WHAT IS THE STUDY?
This study is a clinical trial testing an investigational drug called Eltanexor. The study's aim is to learn the effects of eltanexor in people with HMA Refractory, Higher Risk Myelodysplastic Syndrome (MDS).

Myelodysplastic Syndromes (MDS) are a group of different bone marrow disorders that happen when bone marrow does not produce enough healthy blood cells. Refractory means the disease is resistant to treatment. Higher Risk MDS is more likely to progress to Acute Myeloid Leukemia.

WHY IS IT HAPPENING?
The researchers are working to discover whether the investigational drug is effective and safe for patients with Myelodysplastic Syndromes (MDS). In this study, the researchers will be concentrating on HMA Refractory Higher Risk MDS.

WHO CAN TAKE PART and WHEN DOES IT START?
Adults aged 18 or older with HMA Refractory, Higher Risk Myelodysplastic Syndrome (MDS). Your doctor can fill you in on the other requirements and details of what it is like to participate.

The study is currently open. If you are interested in learning more, your doctor or nurse can tell you more about what it is like to be part of a study.

WHERE IS IT TAKING PLACE?
This is a global study that will enroll approximately 83 participants at about 56 clinical sites, located in Europe, North America and China.

For more information please visit ClinicalTrials.gov Identifier: NCT02649790

Eltanexor (KPT-8602) is an investigational compound. Efficacy and safety have not been established. There is no guarantee that eltanexor will be approved by the FDA or other global health authorities.